Dr. Gelber developed the Q-TWiST method (Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment) for incorporating quality-of-life considerations into treatment comparisons. This quality-adjusted survival technique provides a framework to balance the benefits of disease control against the costs of treatment side effects using threshold utility analysis and patient preferences. The method has been used to demonstrate the quality-of-life benefits of adjuvant chemotherapy for women with operable breast cancer and to evaluate zidovudine for HIV-infected individuals. He was the biostatistician for the Pediatric AIDS Clinical Trials Group (ACTG) Protocol 076 which demonstrated that AZT significantly reduces the risk of maternal- infant transmission of HIV. Dr. Gelber also conducts research on interpretations of meta-analyses and evaluations of late effects of successful treatments for childhood cancers. In addition, he directs Statistical Centers responsible for the design, conduct, analysis and reporting of large-scale, randomized clinical trials evaluating treatments for pediatric malignancies and breast cancer. He has been the Group statistician for the International Breast Cancer Study Group (IBCSG) since 1978.

Ph.D., 1975, Cornell University